0000950170-24-010477.txt : 20240202
0000950170-24-010477.hdr.sgml : 20240202
20240202160518
ACCESSION NUMBER: 0000950170-24-010477
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Evans John M.
CENTRAL INDEX KEY: 0001786304
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39208
FILM NUMBER: 24591336
MAIL ADDRESS:
STREET 1: C/O BEAM THERAPEUTICS INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beam Therapeutics Inc.
CENTRAL INDEX KEY: 0001745999
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-327-8775
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-01-31
0001745999
Beam Therapeutics Inc.
BEAM
0001786304
Evans John M.
C/O BEAM THERAPEUTICS INC.,
238 MAIN STREET
CAMBRIDGE
MA
02142
true
true
false
false
CEO
true
Common Stock
2024-01-31
4
S
false
60000
25.33
D
1058262
D
Common Stock
103000
I
By John M. Evans, III 2018 Irrevocable Trust
Stock Option (Right to Buy)
24.40
2024-01-31
4
A
false
155000
24.40
A
2034-01-31
Common Stock
155000
155000
D
These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $24.93 to $25.92 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023.
This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.
By: /s/ Christine Bellon, Attorney-in-fact
2024-02-02